financetom
Business
financetom
/
Business
/
Natura posts better-than-expected Q2 core earnings, API hits bottom line
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Natura posts better-than-expected Q2 core earnings, API hits bottom line
Aug 13, 2024 5:11 AM

SAO PAULO (Reuters) - Brazilian cosmetic maker Natura &Co late on Monday posted better-than-expected core earnings for the second quarter, but saw its bottom line affected by write-offs as U.S. subsidiary Avon Products filed for bankruptcy protection.

WHY IT'S IMPORTANT

Natura &Co is a cosmetic giant that has been pushing for a turnaround and shedding global assets, including the sales of the Aesop and The Body Shop brands, as it turned its focus to Latin America to integrate Avon and its namesake brand.

BY THE NUMBERS

Natura posted net revenue of 7.35 billion reais ($1.34 billion) for the April-June quarter, up 5.4% from a year earlier and above the 6.78 billion forecast by analysts polled by LSEG.

Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) rose 14.2% to 803.5 million reais. Analysts expected 763.8 million reais.

KEY QUOTE

"We started to see a better trend in the top-line dynamics reflecting a strong performance of the Natura brand, with Brazil and Mexico accelerating pace," CEO Fabio Barbosa said.

API CHAPTER 11

Natura said that Avon Products (API), a U.S.-based non-operating holding that it bought in 2020 as part of its acquisition of Avon, filed for Chapter 11 bankruptcy protection to deal with high debt.

Natura &Co is API's largest creditor and supports the move, committing to a $43 million debtor-in-possession financing and a $125 million offer to buy Avon's non-U.S. operations.

API's move led Natura &Co to post a net loss of 859 million reais in the second quarter, wider than last year's 732 million-real loss, mainly due to write-offs.

MARKET REACTION

JP Morgan analysts said Natura &Co continued to show a good trajectory to deliver the expected results from the Avon integration in Latin America, but results were still polluted by many one-offs and Avon International.

"In this noisy context, we expect a positive share price reaction to the better than anticipated results from LatAm."

($1 = 5.4929 reais)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved